Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 20/20 | 0.75 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14734945 | 1.00 | PIM1 (0.75) | PIM1PIM2PIM3 | |
| SCHEMBL14735127 | 0.93 | PIM1 (0.65) | PIM1PIM2PIM3 | |
| SCHEMBL14735126 | 0.93 | PIM1 (0.65) | PIM1PIM2PIM3 | |
| SCHEMBL14735276 | 0.91 | PIM1 (0.73) | PIM1PIM2PIM3 | |
| SCHEMBL14735279 | 0.91 | PIM1 (0.73) | PIM1PIM2PIM3 | |
| SCHEMBL14735290 | 0.91 | PIM1 (0.61) | PIM1PIM2PIM3 | |
| SCHEMBL14735366 | 0.91 | PIM1 (0.62) | PIM1PIM2PIM3 | |
| SCHEMBL14735288 | 0.91 | PIM1 (0.61) | PIM1PIM2PIM3 | |
| SCHEMBL14735367 | 0.91 | PIM1 (0.62) | PIM1PIM2PIM3 | |
| SCHEMBL14734907 | 0.90 | PIM1 (0.73) | PIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885PIM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.